BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 895 filers reported holding BAXTER INTL INC in Q1 2016. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $5,000 | 0.0% | 124 | +0.8% | 0.05% | +2.2% |
| Q4 2015 | $5,000 | -50.0% | 123 | -60.6% | 0.04% | -51.1% |
| Q3 2015 | $10,000 | -99.9% | 312 | -99.9% | 0.09% | -18.6% |
| Q2 2015 | $8,374,000 | -37.3% | 220,420 | +13.1% | 0.11% | -43.8% |
| Q1 2015 | $13,352,000 | -11.5% | 194,916 | -5.3% | 0.20% | -6.9% |
| Q4 2014 | $15,084,000 | +10.9% | 205,807 | +8.6% | 0.22% | -1.8% |
| Q3 2014 | $13,598,000 | -0.8% | 189,471 | -0.1% | 0.22% | -0.5% |
| Q2 2014 | $13,714,000 | +4.6% | 189,682 | +6.4% | 0.22% | -5.6% |
| Q1 2014 | $13,116,000 | +7.4% | 178,253 | -4.1% | 0.23% | +0.4% |
| Q3 2013 | $12,208,000 | -4.6% | 185,843 | +0.6% | 0.23% | -8.6% |
| Q2 2013 | $12,800,000 | – | 184,790 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |